ReviewJapanese journal of clinical oncology2024
Gastric-type adenocarcinoma of the uterine cervix: clinical features and future directions.
Review in Japanese journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Comparing paclitaxel and platinum-based concurrent chemoradiotherapy with short-term adjuvant chemotherapy versus platinum-based monotherapy concurrent chemoradiotherapy in patients with postoperative gastric-type endocervical adenocarcinoma with high-risk factors for recurrence: a multicenter randomized phase III trial.Journal of gynecologic oncology · 2026Trial
- Artificial intelligence-assisted histopathological diagnosis of endocervical gastric-type adenocarcinoma: a multicenter model development and validation study.The journal of pathology. Clinical research · 2026Article
- The Choice Between Definitive Radiotherapy and Surgery for Cervical Cancer With Different Histology in Current Clinical Practice.The Kaohsiung journal of medical sciences · 2026Article
- Clinicopathological characteristics and outcomes of gastric-type adenocarcinoma of the cervix: a systematic review.AJOG global reports · 2026Review
- Difficulties in Diagnosing Gastric Adenocarcinoma of the Cervix: A Clinical Case and Literature Review.Cureus · 2026Article
- Gastric-Type Cervical Adenocarcinoma: Clinicopathologic Features, Molecular Landscape, and Therapeutic Challenges.Journal of personalized medicine · 2026Review
- Comprehensive clinical analysis of gastric-type endocervical adenocarcinoma: a real-world multicenter study.Annals of medicine · 2025Article
- Diagnostic value of cytology in detecting human papillomavirus-independent cervical malignancies: a nation-wide study in Korea.Journal of pathology and translational medicine · 2025Article
- HPV-Independent Cervical Cancer-A New Challenge of Modern Oncology.International journal of molecular sciences · 2025Review
- Peutz-Jeghers syndrome in gynecological cancers: bibliometric trends, clinical insights, and future directions.Gynecologic oncology reports · 2025Article
- A Comparative Analysis of Usual- and Gastric-Type Cervical Adenocarcinoma in a Japanese Population Reveals Distinct Clinicopathological and Molecular Features with Prognostic and Therapeutic Insights.International journal of molecular sciences · 2025Article
- Advances in cervical cancer: current insights and future directions.Cancer communications (London, England) · 2025Review
- Subtle Presentation of Two Rare Gynecological Cancers in a Single Patient: A Case Report.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The concept of gastric-type mucinous carcinoma of the uterine cervix (GAS) has been accepted worldwide because of its aggressive clinical behaviour and the absence of high-risk human papilloma virus infection. The World Health Organization (WHO) 2020 classification divides cervical tumours into two categories: human papilloma virus-associated and human papilloma virus-independent. Hence, GAS is now classified as an human papilloma virus-independent gastric type. Because clinical studies have reported that GAS is refractory to conventional treatments such as chemotherapy and radiotherapy, especially at an advanced stage, and has aggressive features with widespread dissemination to unusual sites, such as the omentum, peritoneum and distant organs, it is urgent to establish new treatment strategies by comparing the molecular profiles of human papilloma virus-associated adenocarcinomas. A series of genetic mutations characteristic to GAS encourage the development of future treatment strategies such as targeted therapy and immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.